News & Publications

NCCS researchers publish phase Ib results of study conducted at SingHealth IMU

Publication: Journal of Clinical Oncology

Researchers from the National Cancer Centre Singapore presented a poster, titled “A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumours enriched for Epstein-Barr Virus (EBV) related cancers” at the 2012 meeting of the American Society of Clinical Oncology.

 
Melanopsin and Rod–Cone Photoreceptors Play Different Roles in Mediating Pupillary Light Responses
Publication: The Journal of Neuroscience 

Researchers from the Chronobiology Laboratory at Duke-NUS Graduate Medical School published a study “Melanopsin and rod–cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humans” in The Journal of Neuroscience. They compared pupillary light responses in normally sighted individuals (n = 24) with a blind individual lacking rod–cone function. Their findings demonstrate nonredundant roles for rod–cone photoreceptors and melanopsin in mediating pupillary responses to continuous light.
 
Phase I/II study results on hepatocellular carcinoma published
Publication: The Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings

Researchers from the National Cancer Centre Singapore presented a poster, titled "A Phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma" at the 2012 meeting of the American Society of Clinical Oncology. 
 
NCCS researchers present first-in-human phase I study results conducted at SingHealth IMU
Publication: The Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings

An oral presentation on the "First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors" was delivered at the 2012 meeting of the American Society of Clinical Oncology. 
 
NCCS, SGH and Duke-NUS researchers publish results on the use of P16 and cyclin D1 as prognostic markers in carcinoma
Publication: The Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings

Researchers from the National Cancer Centre Singapore, Singapore General Hospital, and Duke-NUS Graduate School Singapore presented their poster, titled "P16 and cyclin D1 (CYD1) as prognostic markers in hypopharyngeal (HSC) and oropharyngeal squamous cell carcinoma (OSC)" at the 2012 meeting of the American Society of Clinical Oncology. 
 
Results on smoking status association with molecular markers published
Publication: The Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings

Researchers from the National Cancer Centre Singapore, Singapore General Hospital, and Duke-NUS Graduate School Singapore presented their poster, titled "Association of smoking status with p16 and cyclin D1 (CCND1) expression with clinical characteristics and overall survival (OS) in oropharyngeal squamous cell carcinoma (OSC)" at the 2012 meeting of the American Society of Clinical Oncology. 


 
Chronobiology Laboratory publishes study on heart rate variability in estimating sleepiness effects on the PVT
Publication: SLEEP 

Researchers from the Chronobiology Laboratory at Duke-NUS Graduate Medical School published their study in the journal Sleep. They found the ECG carries information about a person's vigilance stat and hence, conclude that HRV measures could potentially be used to predict when an individual is at increased risk of attentional failure. Their results suggest that HRV monitoring, either alone or in combination with other physiologic measures, could be incorporated into safety devices to warn drowsy operators when their performance is impaired.
 
NCCS researchers publish phase Ib findings of study conducted at SingHealth IMU
Publication: The Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings

The findings of a research collaboration with the National Cancer Centre Singapore on a "Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC" were presented at the 2011 meeting of the American Society of Clinical Oncology.
 
Clinical trials are essential to advancing medicine

Publication: Lianhe Zaobao

SingHealth's recently launched Investigational Medicine Unit (IMU), is a dedicated early-phase clinical trials facility. It focuses on early phase trials and therefore looks for both healthy and patient volunteers to take part in its studies. But what are volunteers required to do? Dr Darren Lim, Director, SingHealth IMU, explains the role of volunteers, the safeguards in place and dispels common myths.

 
SingHealth opens largest early-phase clinical trial unit
Publication: Strait Times

SingHealth launched a $20 million early-phase clinical research unit, which is located at the heart of SGH Campus. SingHealth IMU is funded by the National Medical Research Council, the Singapore Institute of Clinical Sciences, Duke-NUS Graduate Medical School and SingHealth. The unit, the largest of its kind in Singapore, is a ready platform for local clinician-scientists and external partners to conduct early-stage clinical research. By nurturing clinician-scientists at the forefront of their medical specialty, patients stand to benefit, regardless of whether they participate in clinical trials.
 
SingHealth opens largest early-phase clinical trial unit
Publication: Business Times

SingHealth launched a $20 million early-phase clinical research unit, which is located at the heart of SGH Campus. SingHealth IMU is funded by the National Medical Research Council, the Singapore Institute of Clinical Sciences, Duke-NUS Graduate Medical School and SingHealth. The unit, the largest of its kind in Singapore, is a ready platform for local clinician-scientists and external partners to conduct early-stage clinical research. By nurturing clinician-scientists at the forefront of their medical specialty, patients stand to benefit, regardless of whether they participate in clinical trials.
 
SingHealth opens largest early-phase clinical trial unit
Publication: Lianhe Zaobao

SingHealth launched a $20 million early-phase clinical research unit, which is located at the heart of SGH Campus. SingHealth IMU is funded by the National Medical Research Council, the Singapore Institute of Clinical Sciences, Duke-NUS Graduate Medical School and SingHealth. The unit, the largest of its kind in Singapore, is a ready platform for local clinician-scientists and external partners to conduct early-stage clinical research. By nurturing clinician-scientists at the forefront of their medical specialty, patients stand to benefit, regardless of whether they participate in clinical trials.
 
SingHealth IMU shares insights on clinical trial volunteers
Publication: Lianhe Zaobao

Every year, an average of 5,000 people volunteer to take part in clinical trials conducted by the public healthcare sector here, with the majority enrolling in studies done at hospitals and specialty centres under the SingHealth group. Through these volunteers' selfless contributions, new medical treatments and cures can be discovered, bringing hope to patients.
 
Clinical trials are essential to advancing medicine
Publication: Lianhe Zaobao

SingHealth is boosting its clinical research activities through its new centralised Institutional Review Board, which safeguards ethical standards for research involving humans, as well as a new Investigational Medicine Unit, which focuses on early phase clinical trials. Clinical trials are essential inour search for new treatments and cures, and SingHealth is thus stepping up educational efforts among the general public on what clinical trials are and the roles we can play.
 
Why clinical trials need volunteers
Publication: Straits Times (Mind Your Body)

SingHealth is boosting its clinical research activities through a new Investigational Medicine Unit, which focuses on early phase clinical trials. Clinical trials are essential in our search for new treatments and cures, and SingHealth is stepping up educational efforts among the general public on what clinical trials are and the roles we can play.